Publications by authors named "T Bohnacker"

Claim this Profile
R
Rapid, potent, and persistent covalent chemical probes to deconvolute PI3Kα signaling.
Lukas Bissegger, Theodora A Constantin, Erhan Keles, Luka Raguž, Isobel Barlow-Busch, Thomas Bohnacker

Chem Sci· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PI3K Regulatory Protein p84 Determines Mast Cell Sensitivity to Ras Inhibition-Moving Towards Cell Specific PI3K Targeting?
Julie R Jin, Elena Gogvadze, Ana R Xavier, Thomas Bohnacker, Jan Voelzmann

Front Immunol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4-(Difluoromethyl)-5-(4-((3,5)-3,5-dimethylmorpholino)-6-(()-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders.
Chiara Borsari, Erhan Keles, Denise Rageot, Andrea Treyer, Thomas Bohnacker

J Med Chem· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine Moiety.
Chiara Borsari, Denise Rageot, Florent Beaufils, Thomas Bohnacker, Erhan Keles

ACS Med Chem Lett· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor.
Chiara Borsari, Denise Rageot, Alix Dall'Asen, Thomas Bohnacker, Anna Melone

J Med Chem· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis